Type XX Collagen C-Terminal ELISA for Cancer Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective, non-invasive biomarkers for detecting and monitoring cancer, particularly due to the limited understanding of type XX collagen's role and distribution in cancer, which hinders early detection and treatment response prediction.
Innovation Solution
Development of an enzyme-linked immunosorbent assay (ELISA) to quantify the presence of type XX collagen biomarker (PRO-C20) in blood using a monoclonal antibody that specifically binds to its C-terminus amino acid sequence, enabling detection and monitoring of cancer through immunoassays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional biomarkers are used for cancer detection, then detection capability is achieved, but invasive procedures such as tissue biopsies are required
Solution Approach 1:
The patent uses circulating collagen peptides as intermediary biomarkers that can be detected in blood samples without requiring direct tissue sampling. These peptides serve as mediators between the tumor and the detection system, enabling non-invasive cancer detection through liquid biopsy of blood samples.
2Loss of information
If well-characterized collagens (type I, III, IV) are studied, then functional understanding is achieved, but many collagens including type XX remain unexplored
Solution Approach 1:
The patent focuses specifically on type XX collagen (COL20A1) and its C-terminal peptide sequence, applying local quality by concentrating research and detection efforts on this particular collagen type rather than treating all collagens uniformly. This targeted approach enables detailed functional characterization and detection optimization for COL20A1 specifically.
3Ease of operation
If type XX collagen is detected in blood, then non-invasive cancer detection is enabled, but the biomarker must be specifically targeted due to low expression in most tissues
Solution Approach 1:
The patent changes the detection parameter from whole protein to C-terminal peptide sequence, which enhances detectability and specificity. By targeting the unique C-terminal peptide sequence of type XX collagen rather than the entire protein, the assay achieves higher measurement precision and tissue specificity, enabling reliable non-invasive detection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ELISA assay is robust and sensitive, demonstrating elevated PRO-C20 levels in cancer patients compared to healthy controls, with high levels associated with poor survival rates, providing a reliable tool for cancer detection and prognosis.
Implementation Method 1
contacting a sample from a patient with a monoclonal antibody that specifically binds to a C-terminus amino acid sequence QGASTQGLWE
Implementation Method 2
detecting and determining the amount of binding between said monoclonal antibody and peptides in the sample
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Described herein are immunoassays for detecting and/or monitoring cancer in a patient, comprising contacting a sample from a patient with a monoclonal antibody that specifically binds to a C-terminus amino acid sequence that corresponds to the C-terminus of type XX collagen. Also described are said monoclonal antibodies and immunoassay kits for use in carrying out said immunoassays.